New Delhi: More Indian companies are expected to open new dedicated research and development firms in foreign countries, particularly in the US and Europe, according to a report on Tuesday.

The report by GlobalData, a data and analytics company, showed that Indian pharma players have increased their focus on innovative research and development.

Traditionally, leading Indian drugmakers like Sun Pharma and Dr Reddy’s used to execute their innovative research and development in India through a dedicated research company in foreign countries.

“By demerging research and development units and creating new research and development companies, parent firms de-risk their main business from the risks associated with the failure of research projects without impacting the profit and loss of the main business,” said Prashant Khadayate, Pharma Analyst at GlobalData.

He added that the move will also help research companies “raise more funds from investors”.

On the other hand, some companies have started establishing dedicated research companies in major markets like the US and Europe.

Examples of such Indian pharma companies are Zydus Lifesciences, Glenmark Pharma, Alembic Pharmaceuticals, and Suven Life Sciences.

According to GlobalData’s Pharmaceutical Intelligence Center, as of December 20, 16 drugs were in the pipeline from Phase I to Phase III, with these companies having a base in the US or Europe. Two drugs from these companies are in Phase III.

“Indian pharma companies with their research arms in the US or Europe are certainly benefitting from the local talent in those countries. The pipeline drugs from these companies look promising and are expected to bring rewards for these companies in the future,” Khadayate said.

He noted that other Indian companies will most likely adapt the success model of these companies.

He added that this will not only help Indian companies establish themselves on the innovative research and development front but also fuel their growth globally in the innovative drugs space.

 

 

 

 

 

 

–IANS

Caption : clinical research (Yonhap)